From: How do we know a treatment is good enough? A survey of non-inferiority trials
Freq. (%) (N = 41) | ||
---|---|---|
Methods used | ||
Opinion seeking without evidence base | 7 (17.1) | |
Evidence based without opinion seeking | 11 (26.8) | |
Opinion seeking and evidence based | 17 (41.5) | |
Neither opinion seeking nor evidence based | 6 (14.6) | |
Used opinion seeking methods | 24/41 (58.5) | |
Opinion seeking stakeholderab | Clinicians only | 4 (16.7) |
Patients only | 1 (4.2) | |
Clinicians and patients | 2 (8.3) | |
Clinicians, patients and researchers | 1 (4.2) | |
Clinicians and researchers | 12 (50.0) | |
Research team | 2 (8.3) | |
Missing | 2 (8.3) | |
Opinion seeking recruitment methodab | Convenience | 12 (50.0) |
Relevant mailing lists | 4 (16.7) | |
Convenience and contacting key experts | 4 (16.7) | |
Via a patient and public involvement panel | 3 (12.5) | |
Unclear | 1 (4.2) | |
Opinion seeking method usedab | Direct questioning | 14 (58.3) |
Delphi approach | 1 (4.2) | |
Threshold for clinical efficacy | 7 (29.2) | |
Trade-off/elicitation methods | 2 (8.3) | |
Implementation of the opinion seeking methodab | Survey only | 6 (25.0) |
Face to face meetings only | 10 (42) | |
Face to face meetings and focus groups or interviews | 5 (20.8) | |
Survey, face to face meeting and focus group | 1 (4.2) | |
Missing | 2 (8.3) | |
Used evidence synthesis methods | 28/41 (68.3) | |
Used systematic review of RCTb | Yes | 9 (32.1) |
No | 9 (32.1) | |
Not available at the time of design | 8 (28.6) | |
Missing | 2 (7.1) | |
Evidence used to justify the marginb | Systematic review or meta-analysis of all relevant RCTs | 8 (28.6) |
Observational studies or non-RCTs | 4 (14.3) | |
Reviewed multiple RCTs | 10 (35.7) | |
Evidence from one RCT | 2 (7.1) | |
Missing | 4 (14.3) | |
Used guidelinesb | 22/41 (53.7) | |
Guidelines usedb | EMEA 2006 | 4 (18.2) |
FDA 2010 | 4 (18.2) | |
ICH E10 | 1 (4.5) | |
ICH E9 | 2 (9.1) | |
Missing | 11 (50.0) |